At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
DCC-2618drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies.
In Brief
A Phase 2 clinical trial evaluating DCC-2618 for Gastrointestinal Stromal Tumors. Completed, enrolled 39 participants across 9 sites.
Detailed Summary
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumors
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartApr 2020
Primary CompletionFeb 2021
Study CompletionAug 2022
TodayJul 2026
First PostedFeb 25, 2020
Enrollment StartApr 23, 2020
Primary CompletionFeb 26, 2021
Study CompletionAug 23, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.4 years ago
Interventions
DCC-2618drug
Oral kinase inhibitor